|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-2-9
|
|
pubmed:abstractText |
To determine the maximum tolerated dose of oblimersen, an antisense oligonucleotide directed to the Bcl-2 mRNA, in combination with cisplatin and 5-flourouracil in patients with advanced gastric and esophageal carcinoma.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1537-453X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
33
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
61-5
|
|
pubmed:meshHeading |
pubmed-meshheading:19738454-Adult,
pubmed-meshheading:19738454-Aged,
pubmed-meshheading:19738454-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19738454-Cisplatin,
pubmed-meshheading:19738454-Drug Therapy, Combination,
pubmed-meshheading:19738454-Esophageal Neoplasms,
pubmed-meshheading:19738454-Esophagogastric Junction,
pubmed-meshheading:19738454-Female,
pubmed-meshheading:19738454-Fluorouracil,
pubmed-meshheading:19738454-Humans,
pubmed-meshheading:19738454-Male,
pubmed-meshheading:19738454-Maximum Tolerated Dose,
pubmed-meshheading:19738454-Middle Aged,
pubmed-meshheading:19738454-Neoplasm Staging,
pubmed-meshheading:19738454-Oligonucleotides, Antisense,
pubmed-meshheading:19738454-Pilot Projects,
pubmed-meshheading:19738454-Prognosis,
pubmed-meshheading:19738454-Stomach Neoplasms,
pubmed-meshheading:19738454-Survival Rate,
pubmed-meshheading:19738454-Thionucleotides,
pubmed-meshheading:19738454-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma.
|
|
pubmed:affiliation |
Department of Oncology, Montefiore-Einstein Cancer Center, New York Cancer Consortium Coordinating Center, Bronx, New York 10461, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I,
Research Support, N.I.H., Extramural
|
